Sabag Mark

Sabag Mark, EVP of International Markets, has demonstrated a clear selling bias in his transactions involving Teva Pharmaceutical Industries (TEVA), the only company in which his recent trades have been reported. Over 27 filings, his total sell transactions amount to $12.34 million, dwarfing his $2.21 million in buys—a nearly six-to-one ratio favoring disposals. Notably, his five most recent transactions since December 2025 have all been sales, including a $1.87 million disposal on March 17, 2026, following two larger December 2025 sales totaling $6.23 million ($2.82 million and $3.41 million). The pattern shows intermittent but substantial sell-offs, with earlier disposals of $2.89 million in February 2025 and $1.35 million in March 2024. The transactions reveal a consistent focus on TEVA, with no activity in other equities. While many filings represent minor or non-monetary events (such as awards or modifications), the monetarily significant transactions skew decisively toward divestment. The $2.21 million buy—linked to a December 2025 modification—stands as the sole counterpoint to this trend. Given the absence of recent purchases and the continuation of sales into 2026, Sabag’s trading history suggests a prolonged reduction in his TEVA position rather than active portfolio rebalancing. The sales, often clustered in multi-million-dollar increments, indicate a deliberate unwinding rather than routine diversification.